| Name | Title | Contact Details |
|---|
South Oaks Hospital and Broadlawn Manor is a Amityville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
US Corporate Wellness is the nation`s premier employee wellness provider and one of only 8 national firms to earn Full Accreditation through URAC as a Comprehensive Wellness Provider. We provide a strategy that is tailored to each of our partners to allow maximum engagement and ROI.
Covenant Care is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Covenant Care is based in Aliso Viejo, CA. You can find more information on Covenant Care at www.covenantcare.com
About Arrhythmia Research Technology, Inc. The Company through itswholly-owned subsidiary, Micron Products, Inc. manufacturescomponents, devices and equipment primarily for the medical anddefense industries. Micron is engaged in the production and sale ofsilver/silver chloride coated and conductive resin sensors used ascomponent parts in the manufacture of integrated disposableelectrophysiological sensors. These disposable medical devices areused worldwide in the monitoring of electrical signals in variousmedical applications. The Company has expanded into customthermoplastic injection molded products with a full array of design,engineering and production services and management. The addition ofan orthopedic implant machining operation produces quick-turn, highvolume and patient-specific, finished orthopedic implants. TheCompany also has developed and distributes a customizable proprietarysignal-averaging electrocardiography (SAECG) software used in thedetection of certain heart arrhythmias and that is reconfigurable fora variety of hardware platforms.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.